StemCell Therapy

Equities analysts expect LianBio (NASDAQ:LIAN Get Rating) to announce earnings per share (EPS) of ($0.26) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for LianBios earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.31). The firm is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that LianBio will report full-year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.07). For the next year, analysts expect that the business will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.20) to ($1.44). Zacks Investment Researchs EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for LianBio.

LianBio (NASDAQ:LIAN Get Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts consensus estimates of ($0.72) by $0.44.

Several institutional investors have recently modified their holdings of LIAN. Victory Capital Management Inc. acquired a new stake in LianBio during the 4th quarter worth $1,069,000. Bank of America Corp DE acquired a new stake in LianBio during the 4th quarter worth $519,000. Alps Advisors Inc. acquired a new stake in LianBio during the 4th quarter worth $750,000. Element Capital Management LLC acquired a new stake in LianBio during the 4th quarter worth $124,000. Finally, TD Asset Management Inc. acquired a new position in shares of LianBio in the 4th quarter valued at $954,000. 62.99% of the stock is owned by institutional investors and hedge funds.

Shares of LianBio stock traded down $0.26 during midday trading on Thursday, reaching $4.91. The company had a trading volume of 435,320 shares, compared to its average volume of 411,834. The companys fifty day moving average is $4.19. LianBio has a 1-year low of $2.61 and a 1-year high of $16.37.

About LianBio (Get Rating)

Lianbio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor IO combinations; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric and other cancers; BBP-398 for solid tumors; Omilancor for ulcerative and Crohn's disease; NH-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

Recommended Stories

Get a free copy of the Zacks research report on LianBio (LIAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.

See more here:
LianBio (NASDAQ:LIAN) Expected to Post Earnings of -$0.26 Per Share - Defense World

This entry was posted on April 26, 2022 at 1:46 am and is filed under Opthalmology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |